Blockade of renin-angiotensin system ameliorates renal injury in NIDDM model rats

Abstract

Background. Recently, inhibition of the renin-angiotensin system has been reported to be effective for patients with diabetic nephropathy. In this study, we examined the renal protective effects of candesartan cilexetil (TCV-116) in Wistar fatty rats, a model of non-insulin-dependent diabetes mellitus (NIDDM) with renal injuries.

Methods. Twelve-week-old Wistar fatty rats received candesartan cilexetil (0.3 or 1 mg/kg) or enalapril (10 mg/kg) daily, administered orally, for 16 weeks. Routine laboratory parameters, such as urinary albumin and total protein excretion, were measured every 4 weeks, and renal function tests and histopathological studies were carried out at the end of the experiment.

Results. In the 12-week-old Wistar fatty rats, plasma glucose and insulin levels were significantly higher than those in age-matched Wistar lean rats (normal controls). Urinary albumin and total protein excretion was slightly but significantly increased as compared to these parameters in Wistar lean rats, and increased further with time. Daily administration of candesartan cilexetil or enalapril inhibited the increase in urinary albumin and total protein excretion without affecting plasma glucose and insulin levels. In histopathological studies, candesartan cilexetil (0.3 and 1 mg/kg) and enalapril (10 mg/kg) prevented the glomerular injury observed in vehicle-treated rats. Candesartan cilexetil (1 mg/kg) and enalapril also inhibited tubular changes. Systolic blood pressure in the drug-treated groups was significantly decreased compared with that in vehicle-treated rats.

Conclusions. Inhibitors of the renin-angiotensin system ameliorated proteinuria and the pathological changes of renal injuries in this NIDDM model. Candesartan cilexetil may be useful for the treatment of NIDDM patients with renal damage.